AMY LAMPARELLA: Open Payments
NPI 1093704652 · ELLICOTT CITY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$440 in 18 payments from 9 companies in 2025. Trend: 2023 $787 · 2024 $812 · 2025 $440
Food & beverage: $440
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $236 |
| ABBVIE INC. | 2 | $43 |
| Novo Nordisk Inc | 2 | $42 |
| Abbott Laboratories | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| SANOFI PASTEUR INC. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
| Exact Sciences Corporation | 1 | $14 |
Products named: Veozah, VRAYLAR, Ozempic, FREESTYLE LIBRE 3, CAPVAXIVE, Ambulatory Monitoring & Diagnostics Undivided, FLUZONE HIGH-DOSE, CAPLYTA.
Industry payments across MD — which companies pay providers there.
